Profil
Greg Mann is currently working as the Media & Investor Relations Contact at Nkarta, Inc. He previously worked as the Director-Investor Relations at Abgenix, Inc., Executive Director-IR & Corporate Communications at FibroGen, Inc., and Vice President-Investor Relations at Kite Pharma, Inc.
Aktive Positionen von Greg Mann
Unternehmen | Position | Beginn |
---|---|---|
NKARTA, INC. | Investor Relations Contact | 01.02.2020 |
Ehemalige bekannte Positionen von Greg Mann
Unternehmen | Position | Ende |
---|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Investor Relations Contact | 01.01.2006 |
KITE PHARMA INC | Investor Relations Contact | - |
FIBROGEN, INC. | Investor Relations Contact | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
FIBROGEN, INC. | Health Technology |
NKARTA, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |